Bio Blast Pharma, a clinical-stage biotech developing treatments for rare and ultra-rare genetic diseases, announced terms for its IPO on Tuesday. The Tel Aviv, Israel-based company plans to raise $40 million by offering 3.3 million shares at a price range of $11 to $13. At the midpoint of the proposed range, Bio Blast would command a fully diluted market value of $178 million.
Bio Blast Pharma, which was founded in 2012, plans to list on the NASDAQ under the symbol ORPN. Oppenheimer and Roth Capital are the joint bookrunners on the deal.
